Barclays Downgrades Alnylam Pharmaceuticals (ALNY) to Equalweight
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Barclays downgraded Alnylam Pharmaceuticals (NASDAQ: ALNY) from Overweight to Equalweight with a price target of $50.00 (from $85.00).
Shares of Alnylam Pharmaceuticals closed at $70.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Macquarie Downgrades Alliant Energy (LNT) to Neutral
- Stifel Downgrades Humana (HUM) to Hold
- Barclays Downgrades Apple (AAPL) to Equalweight, Concerned India/China Will not Emerge As Growth Catalysts
Create E-mail Alert Related CategoriesAnalyst PT Change, Downgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!